Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

von Roemeling C., CA-4948 PCNSL NHCC Meeting 2023

Monday, December 11, 2023 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Curis Inc. presented an overview of its pipeline and ongoing studies at the NHCC Meeting 2023. The company highlighted its collaborations and the development of therapies such as Emavusertib (CA-4948) for various lymphomas. Additionally, they provided insights into their compassionate use policy and patient engagement strategies.

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What did Curis present at the NHCC Meeting 2023?

Curis presented an overview of its pipeline and ongoing studies, focusing on CA-4948.

What is Emavusertib (CA-4948)?

Emavusertib (CA-4948) is a therapy developed by Curis for various lymphomas.

What is the TakeAim program?

The TakeAim program includes studies for Lymphoma, Leukemia, and CLL sponsored by Curis.

How does Curis engage with patients?

Curis engages with patients through its compassionate use policy and ongoing studies.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Curis CA-4948 Primary CNS Lymphoma TakeAim Lymphoma TakeAim Leukemia
Last updated: Dec 11, 2023

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →